Given that oncogenic EVI1 modulates TGF-β signaling [24,25], ccRCC cases with EVI1 over-expression might show differential benefit from immunotherapy, and further studies may warranted to assess the potential benefit of targeting EVI1. This evidence concerns the gene MECOM and nonpapillary renal cell carcinoma.